Shoutaro Tsuji

Maebashi, 3710823, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

A novel bicistronic vector inducing balanced alternative splicing for antibody production.

A novel bicistronic vector inducing balanced alternative splicing for antibody production.

Journal: Scientific reports

Published: February 05, 2026

Flow-Sensitive HEG1 Controls eNOS Activity to Prevent Endothelial Dysfunction, Hypertension, and Atherosclerosis.

Flow-Sensitive HEG1 Controls eNOS Activity to Prevent Endothelial Dysfunction, Hypertension, and Atherosclerosis.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: October 09, 2025

Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence.

Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence.

Journal: Frontiers in immunology

Published: September 27, 2024

HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.

HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.

Journal: Circulation

Published: December 15, 2023

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.

Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: August 31, 2023

Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.

Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.

Journal: International journal of cancer

Published: June 12, 2023

Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.

Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.

Journal: Proceedings of the Japan Academy. Series B, Physical and biological sciences

Published: February 12, 2023

Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.

Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.

Journal: Pathology international

Published: January 11, 2021

HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.

HEG1 Is a Highly Specific and Sensitive Marker of Epithelioid Malignant Mesothelioma.

Journal: The American journal of surgical pathology

Published: March 25, 2020

HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.

HEG1-responsive microRNA-23b regulates cell proliferation in malignant mesothelioma cells.

Journal: Biochemical and biophysical research communications

Published: March 20, 2020

Endogenous neurotoxin-like protein Ly6H inhibits alpha7 nicotinic acetylcholine receptor currents at the plasma membrane.

Endogenous neurotoxin-like protein Ly6H inhibits alpha7 nicotinic acetylcholine receptor currents at the plasma membrane.

Journal: Scientific reports

Published: November 27, 2019

HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.

HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion.

Journal: Diagnostic cytopathology

Published: November 11, 2019

Showing 1-12 of 26

Last Updated: 09/26/2026